Heart check for sickle cell drug: early safety trial begins

NCT ID NCT07023029

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 trial studied how etavopivat, a potential new medicine for sickle cell disease and thalassemia, affects the heart's electrical activity. Thirty-three healthy adults received single doses of etavopivat, a placebo, or an approved heart medication (moxifloxacin) to compare effects. The goal was to check for any heart rhythm changes before testing the drug in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Etavopivat
What this could lead to
If successful, this study will confirm that etavopivat is safe for the heart, supporting its further development as a treatment for sickle cell disease and thalassemia.
What could go wrong
This is an early, small study in healthy volunteers, not patients. It only looks at heart effects, not whether the drug works for the disease. Unexpected heart risks could still emerge in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • PAREXEL Intl - EPCU-Baltimore

    Baltimore, Maryland, 21225, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.